marine drugs

IMPACT FACTOR 4.9

Indexed in: PubMed

CITESCORE 9.6

an Open Access Journal by MDPI

3D Cell Culture Based on Marine Resources

Guest Editor:

Prof. Dr. Jong-Young Kwak
1. Department of Pharmacology, School of Medicine, Ajou University, Worldcup-Ro 164, Suwon 16499, Republic of Korea
2. 3D Immune System Imaging Core Center, Ajou University, Suwon 16499, Republic of Korea
3. Immune-Network Pioneer Research Center, Ajou University Medical Center, Suwon 16499, Republic of Korea

Deadline for manuscript submissions:
closed (20 December 2020)

Message from the Guest Editor

Three-dimensional (3D) cell culture leads to more predictive models for drug discovery and tissue regeneration. An ideal 3D culture model has not yet been defined due to the loss of extracellular matrix-like scaffolds, although various 3D cell culture model systems require such scaffolds for 3D cell growth. Marine origin polymers have been used as scaffolds for 3D cell culture and will be developed as biomaterials for bio-ink in bioprinting. Thus, many polymers such as alginates, carrageenans, fucoidans, and chitosans from marine resources, including fish, algae, crustaceans, bacteria, cyanobacteria, actinobacteria, and fungi, are considered to be promising biomaterials for 3D cell and tissue culture. In addition, the biological assays of bio-active materials from marine resources using 3D culture rather than two-dimensional (2D) culture have been expanded. This Special Issue aims to provide an overview of the current research in 3D culture systems employing marine natural products as biomaterials. As Guest Editor of this Special Issue, I cordially invite contributions in the form of original research articles or reviews on the subject of this advancing research field.

marine drugs

IMPACT FACTOR 4.9 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker
Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
𝕏@Marine_Drugs